Skip to content
    PODD
    Earnings call· Jun 2026(Q2 FY26)

    INSULET Q2 FY26 earnings call PODD

    Aug 5, 2026 Source

    Executive summary

    Insulet Q2 FY26 — Strong Revenue Growth, Type 2 Retention Challenges Lead to Revised Outlook

    Insulet delivered strong Q2 FY26 results with robust revenue growth and significant margin expansion, driven by demand for Omnipod across markets. However, the company revised its full-year revenue outlook due to unexpected challenges in Type 2 customer utilization and retention, particularly in the first 90 days of therapy. Management is implementing decisive actions to address these execution challenges and remains confident in the long-term opportunity within the underpenetrated Type 2 market.

    Highlights

    5

    • Total company revenue grew 23% year-over-year on a constant currency basis, exceeding expectations.

    • Adjusted operating margin increased 140 basis points year-over-year to 19.3%.

    • Adjusted EPS increased approximately 42% to $1.36, nearly twice the rate of revenue growth.

    • Global new customer starts increased sequentially and year-over-year, contributing to 23% growth in the global customer base.

    • Added coverage for an additional 6.5 million lives and reduced prior authorization barriers for approximately 10 million lives.

    Concerns

    4

    • Lower rates of utilization and retention among Type 2 customers were more pronounced than anticipated, leading to a revised full-year revenue outlook.

    • Full-year 2026 total company revenue growth outlook revised down to 20%-22% (constant currency).

    • U.S. Omnipod growth outlook revised down to 17%-19% for the full year.

    • Slightly lower positive pricing anticipated due to timing and mix of commercial investments, accounting for 1/3 of the guidance update.

    Guidance & targets

    22
    CategoryTargetConfidence
    Total Company Revenue Growth
    20%-22%
    high materiality
    High
    U.S. Omnipod Revenue Growth
    17%-19%
    high materiality
    High
    International Omnipod Revenue Growth
    30%-32%
    high materiality
    High
    Total Omnipod Revenue Growth
    21%-23%
    high materiality
    High
    FX Contribution to Total Company/Omnipod Revenue
    100 bps
    medium materiality
    High
    FX Contribution to International Omnipod Revenue
    300 bps
    medium materiality
    High
    Adjusted Operating Margin Expansion
    approximately 100 basis points
    high materiality
    High
    Net Interest Expense
    $40 million
    medium materiality
    High
    Non-GAAP Tax Rate
    20%-21%
    medium materiality
    High
    Shares Outstanding
    approximately 70 million
    medium materiality
    High
    Adjusted EPS Growth
    at least 30%
    high materiality
    High
    Free Cash Flow
    down modestly from 2025 levels
    medium materiality
    Medium
    Omnipod Revenue Growth
    18%-20%
    high materiality
    High
    Total Company Revenue Growth
    17.5%-19.5%
    high materiality
    High
    FX Headwind to Total Company/Omnipod Revenue
    approximately 50 basis points
    medium materiality
    High
    U.S. Omnipod Revenue Growth
    14%-16%
    high materiality
    High
    International Omnipod Revenue Growth
    28%-30%
    high materiality
    High
    FX Headwind to International Omnipod Revenue
    approximately 200 basis points
    medium materiality
    High
    Total Company Constant Currency Revenue Growth Exit Rate
    mid-teens
    high materiality
    High
    Total Company Constant Currency Revenue Growth
    consistent with or better than mid-teens exit rate
    high materiality
    Medium
    Adjusted Operating Margin Expansion
    approximately 100 basis points annually
    high materiality
    High
    Adjusted EPS CAGR
    more than 25%
    high materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    U.S. Omnipod
    Driven by continued demand across both Type 1 and Type 2 customers.
    		—20%——
    International Omnipod
    Driven primarily by volume and continued favorable price/mix realization.
    Reported growth: >35%New users in Australia: #1 insulin pumpNew market entry: Spain
    		—33%——

    Operational metrics

    20
    Total Company Revenue
    $802 million
    Q2 FY26

    Reported basis.

    Total Company Revenue Growth
    22.7%YoY
    Q2 FY26

    Reported growth was 23.5%.

    Adjusted Gross Margin
    72.9%up 320 bps YoY
    Q2 FY26
    Adjusted Operating Margin
    19.3%up 140 bps YoY
    Q2 FY26
    Adjusted EPS
    $1.36up 41.5% from $1.17
    Q2 FY26

    Increased at nearly twice the rate of revenue growth.

    Cash and Investments Balance
    $535 million
    Q2 FY26
    Revolving Credit Facility
    $500 million
    Q2 FY26
    Global New Customer Starts
    increased sequentially and year-over-year
    Q2 FY26
    U.S. New Customer Starts from MDI Users
    >85%
    Q2 FY26
    U.S. New Customer Starts from Type 2 Diabetes
    >40%
    Q2 FY26
    U.S. Prescriber Base
    32,000up 27% YoY
    Q2 FY26
    Payer Coverage Added
    6.5 million
    Q2 FY26
    Prior Authorization Barriers Reduced
    approximately 10 million
    Q2 FY26
    Omnipod Discover Patient Users
    12,000
    Current

    Cloud-based platform for patients with diabetes.

    Omnipod Discover HCP Users
    1,600
    Current

    Cloud-based platform for health care professionals.

    U.S. Adult Basal-Bolus Insulin Users
    2.5 million
    Current

    Type 2 diabetes population.

    U.S. Basal-Only Insulin Users
    3 million
    Current

    Type 2 diabetes population who may benefit from AID therapy.

    Type 2 Patients Managed in Primary Care
    70%
    Current
    Net Interest Expense
    $9.9 million
    Q2 FY26
    Adjusted Tax Rate
    19.8%
    Q2 FY26

    Industry KPIs

    9
    MetricValueDetails
    System utilizationslightly down
    Pricing realized pricestable to slightly up
    New product launch rampOmnipod 5 algorithm enhancements
    Procedure volume growth23%%
    FCF conversion leverage guidance—
    Installed base system placements23%%
    Sales force commercial capacity build>32,000HCPs
    Indicated addressable patient population~2.5 millionusers
    Pivotal trial clinical evidence milestonesimproved time and range and time and tight range

    Product announcements

    2
    ProductTypeDetails
    Omnipod Discoverlaunch
    Omnipod 5 algorithm enhancementsupdate

    Risks & headwinds

    3
    Lower utilization and retention among Type 2 customersQ2 FY26, expected to continue through H2 FY26

    Accounts for approximately 2/3 of the change to prior full-year guidance.

    Mitigation: Expanding customer care team, changing sales force compensation to prioritize retention, refining sample deployment, rolling out Omnipod Discover, accelerating customer data platform development.

    Slower new customer starts than anticipatedQ1 FY26

    Accounts for approximately 1/3 of the change to prior full-year guidance (combined with pricing).

    Mitigation: Overall commercial efforts, including sales force expansion and DTC activations.

    Slightly lower positive pricingFull Year 2026

    Accounts for approximately 1/3 of the change to prior full-year guidance (combined with NCS).

    Mitigation: Timing and mix of commercial investments that support customer access and long-term growth, rather than competitive pricing dynamics.

    What to watch in Q3 FY26

    5

    Type 2 customer retention and utilization rates

    Next quarter (Q3 FY26 results)
    CurrentLower than anticipated, particularly in the first 90 days.
    TargetImproved stabilization of retention rates, especially post-90 days.

    Why it matters

    This is the primary driver of the revised full-year guidance and a key factor for long-term Type 2 market penetration.

    We're updating our full year revenue outlook to incorporate the utilization and retention trends we are seeing within our Type 2 customer base and to reflect the time required for the actions we are taking to translate into improved customer success.

    Q&A highlights

    6

    What changed regarding Type 2 trends since ADA, when did attrition start, and what are the assumptions for 2027 regarding competition and pricing given the U.S. exit rate?

    Ashley acknowledged accountability for not identifying Type 2 trends sooner, stating Q2 saw emerging retention/utilization issues. She emphasized it's an execution challenge, not structural (not pricing, competition, or GLP-1 related). Flavia added that the 2027 outlook contemplates competitive entrants and stable pricing, and does not assume improvement from current actions.

    “I just need to acknowledge upfront that we should have understood some of these Type 2 trends sooner and done a better job of adapting our commercial and customer service model to the needs of this really important customer base, which is the Type 2. And as CEO, I take accountability for that.”

    asked by Robert Marcus · answered by Ashley McEvoy

    2 min read6 chapters

    Detailed Narrative

    01

    Q2 Performance Highlights

    Insulet reported strong Q2 FY26 results, with total company revenue growing 23% constant currency to $802 million, exceeding expectations. This was driven by robust demand for Omnipod in both U.S. and international markets, alongside favorable price/mix. Profitability also expanded significantly, with adjusted operating margin up 140 basis points to 19.3% and adjusted EPS increasing 42% to $1.36, demonstrating strong earnings leverage.

    02

    Type 2 Diabetes Market Dynamics and Challenges

    While demand for Omnipod among Type 2 customers remains strong, representing over 40% of new customer starts, the company observed lower utilization and retention rates, particularly within the first 90 days of therapy. Management attributes this to an execution challenge in adapting its commercial model and customer support to the unique needs of Type 2 Podders, who often have different emotional burdens, higher comorbidities, and are managed by PCPs. This led to a revised full-year revenue outlook.

    03

    Actions to Improve Type 2 Retention and Utilization

    In response to the Type 2 challenges, Insulet is implementing decisive actions. These include expanding its customer care team, changing sales force compensation to prioritize longer-term retention over new starts, refining sample deployment to target high-benefit patients, and rolling out new technology platforms like Omnipod Discover. Omnipod Discover, a cloud-based platform for providers and patients, has shown promising early results in improving clinical outcomes and retention among its 12,000 users and 1,600 HCPs.

    04

    Innovation Pipeline and Future Products

    Insulet is advancing a robust innovation roadmap, including annual algorithm enhancements for Omnipod 5, the upcoming Omnipod 6 (with pivotal STRIVE data showing improved time in range), and a breakthrough fully closed-loop system for Type 2 diabetes. The fully closed-loop system, designed for simplicity with no bolusing or manual titration, is expected to have a 510(k) submission in 2027 and aims to broaden AID access, especially for the 70% of Type 2 patients managed in primary care.

    05

    Commercial Capabilities and Market Access

    The company continues to invest in its market-leading brand, direct-to-consumer (DTC) activations, professional education, and sales force expansion. Efforts to expand access and affordability resulted in adding coverage for 6.5 million lives and simplifying prior authorization requirements for approximately 10 million lives during the quarter, reflecting a strategy focused on broad access rather than exclusionary positions.

    06

    Long-Term Outlook and Strategic Pillars

    Despite the near-term adjustment to revenue guidance, Insulet remains highly confident in the long-term opportunity, citing AID's significant underpenetration, its robust innovation pipeline, expanding commercial capabilities, unmatched manufacturing network, and recurring revenue business model. The company expects to provide an updated long-range outlook on its Q4 call, but anticipates delivering top-tier revenue growth, meaningful margin expansion, and strong earnings growth.

    AI-generated summary of the company’s earnings call. Not investment advice.